Alkermes Plc (ALKS)
47.03
+0.05
(+0.11%)
USD |
NASDAQ |
Nov 13, 16:00
47.02
-0.01
(-0.02%)
Pre-Market: 19:59
Alkermes Enterprise Value : 8.718B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 8.718B |
| November 12, 2026 | 8.710B |
| November 11, 2026 | 8.863B |
| November 10, 2026 | 8.624B |
| November 09, 2026 | 8.574B |
| November 06, 2026 | 8.528B |
| November 05, 2026 | 8.300B |
| November 04, 2026 | 8.527B |
| November 03, 2026 | 8.493B |
| November 02, 2026 | 8.358B |
| October 30, 2026 | 8.434B |
| October 29, 2026 | 8.439B |
| October 28, 2026 | 8.419B |
| October 27, 2026 | 8.263B |
| October 26, 2026 | 8.283B |
| October 23, 2026 | 8.147B |
| October 22, 2026 | 8.239B |
| October 21, 2026 | 8.122B |
| October 20, 2026 | 8.227B |
| October 19, 2026 | 8.036B |
| October 16, 2026 | 7.742B |
| October 15, 2026 | 7.554B |
| October 14, 2026 | 7.382B |
| October 13, 2026 | 7.491B |
| October 12, 2026 | 7.581B |
| Date | Value |
|---|---|
| October 09, 2026 | 7.639B |
| October 08, 2026 | 7.555B |
| October 07, 2026 | 7.780B |
| October 06, 2026 | 7.814B |
| October 05, 2026 | 8.001B |
| October 02, 2026 | 7.831B |
| October 01, 2026 | 7.628B |
| September 30, 2026 | 7.624B |
| September 29, 2026 | 7.752B |
| September 28, 2026 | 7.643B |
| September 25, 2026 | 7.760B |
| September 24, 2026 | 7.750B |
| September 23, 2026 | 7.974B |
| September 22, 2026 | 8.169B |
| September 21, 2026 | 8.318B |
| September 18, 2026 | 8.186B |
| September 17, 2026 | 8.742B |
| September 16, 2026 | 8.635B |
| September 15, 2026 | 8.628B |
| September 14, 2026 | 8.594B |
| September 11, 2026 | 8.618B |
| September 10, 2026 | 8.641B |
| September 09, 2026 | 8.522B |
| September 08, 2026 | 8.537B |
| September 04, 2026 | 8.640B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amarin Corp. Plc | -78.32M |
| Prothena Corp. Plc | 153.83M |
| Cue Biopharma, Inc. | 75.71M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 16.29M |
| Revenue (Quarterly) | 480.13M |
| Total Expenses (Quarterly) | 463.84M |
| EPS Diluted (Quarterly) | 0.0924 |
| Gross Profit Margin (Quarterly) | 75.88% |
| Profit Margin (Quarterly) | 3.39% |
| Earnings Yield | -0.03% |
| Operating Earnings Yield | 1.15% |
| Normalized Earnings Yield | 0.2148 |